Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors.
Bocchini M, Tazzari M, Ravaioli S, Piccinini F, Foca F, Tebaldi M, Nicolini F, Grassi I, Severi S, Calogero RA, Arigoni M, Schrader J, Mazza M, Paganelli G. Bocchini M, et al. Among authors: severi s. Front Oncol. 2023 May 23;13:1136331. doi: 10.3389/fonc.2023.1136331. eCollection 2023. Front Oncol. 2023. PMID: 37287922 Free PMC article.
Theragnostic in neuroendocrine tumors.
Marini I, Sansovini M, Bongiovanni A, Nicolini S, Grassi I, Ranallo N, Monti M, DI Iorio V, Germanò L, Caroli P, Sarnelli A, Paganelli G, Severi S. Marini I, et al. Among authors: severi s. Q J Nucl Med Mol Imaging. 2021 Dec;65(4):342-352. doi: 10.23736/S1824-4785.21.03426-9. Epub 2021 Dec 9. Q J Nucl Med Mol Imaging. 2021. PMID: 34881852
177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials.
Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M, Di Paolo A, Grassi I, Liverani C, Calabrese C, Ranallo N, Matteucci F, Paganelli G, Severi S. Bongiovanni A, et al. Among authors: severi s. Cancers (Basel). 2022 Dec 7;14(24):6022. doi: 10.3390/cancers14246022. Cancers (Basel). 2022. PMID: 36551507 Free PMC article.
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen).
Belli ML, Sarnelli A, Mezzenga E, Cesarini F, Caroli P, Di Iorio V, Strigari L, Cremonesi M, Romeo A, Nicolini S, Matteucci F, Severi S, Paganelli G. Belli ML, et al. Among authors: severi s. Front Oncol. 2020 Nov 5;10:531660. doi: 10.3389/fonc.2020.531660. eCollection 2020. Front Oncol. 2020. PMID: 33251129 Free PMC article.
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, Monti M, Caroli P, Sarnelli A, Diano D, Di Iorio V, Grana CM, Cittanti C, Pieri F, Severi S, Paganelli G. Nicolini S, et al. Among authors: severi s. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3260-3267. doi: 10.1007/s00259-021-05236-z. Epub 2021 Feb 18. Eur J Nucl Med Mol Imaging. 2021. PMID: 33604690 Free PMC article. Clinical Trial.
HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Liverani C, Spadazzi C, Ibrahim T, Pieri F, Foca F, Calabrese C, De Vita A, Miserocchi G, Cocchi C, Vanni S, Ercolani G, Cavaliere D, Ranallo N, Chiadini E, Prisinzano G, Severi S, Sansovini M, Martinelli G, Bongiovanni A, Mercatali L. Liverani C, et al. Among authors: severi s. Front Endocrinol (Lausanne). 2023 Jan 20;13:1045038. doi: 10.3389/fendo.2022.1045038. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36743926 Free PMC article.
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study.
Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, Di Iorio V, Monti M, Scarpi E, Bongiovanni A, Altini M, Urso L, Cittanti C, Matteucci F, Severi S. Paganelli G, et al. Among authors: severi s. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):152-160. doi: 10.1007/s00259-020-04873-0. Epub 2020 May 29. Eur J Nucl Med Mol Imaging. 2021. PMID: 32472437 Clinical Trial.
298 results